Latham’s Life Sciences Licensing Practice has experience in the full spectrum of life sciences industry sectors, including biologics, biosimilars, diagnostics and medical devices, pharmaceuticals and therapeutics. We have advised clients in complex deals that have been nominated for or won industry-leading awards such as LMG’s Life Sciences Deal of the Year (2018), In Vivo’s “Alliance of the Year” (2016), and Thomson Reuters Allicense Breakthrough Award for Biopharmaceutical Licensing Deal of the Year (2015).

Latham has deep experience advising clients on life sciences-related transactions, such as:

• Complex global strategic alliances, joint ventures, spinouts and other special purpose business structures
• Intellectual property licensing, monetization and exploitation
• Co-development and co-promotion agreements
• Academic and research agreements
• Manufacturing, supply and distribution agreements
• Intellectual property advice in support of mergers, acquisitions or divestitures of genomics, pharmaceutical and medical device assets
• Day-to-day counseling on commercial transactions

The lawyers’ in-depth knowledge of the life sciences markets and the science that underpins them enables the firm to work with its clients to identify, conceptualize, and develop creative solutions to the business and legal issues that arise in the course of a complex life sciences transaction.

Latham’s Life Sciences Licensing Practice has experience in the full spectrum of life sciences industry sectors, including biologics, biosimilars, diagnostics and medical devices, pharmaceuticals and therapeutics. We have advised clients in complex deals that have been nominated for or won industry-leading awards such as LMG’s Life Sciences Deal of the Year (2018), In Vivo’s “Alliance of the Year” (2016), and Thomson Reuters Allicense Breakthrough Award for Biopharmaceutical Licensing Deal of the Year (2015).

Other notable recent experience includes:

• Prothena’s Collaboration with Celgene Corporation to develop new therapies for neurodegenerative diseases, valued up to US$2.2 billion
• CytomX Therapeutics’ Collaboration with Amgen to co-develop a highly validated oncology target expressed on multiple human cancer types, valued up to US$1.5 billion
• Juno Therapeutics’ Collaboration with Celgene Corporation to develop and commercialize immunotherapies, valued up to US$1 billion, and subsequent license for CD19
• Allergan’s Collaboration with Editas Medicine to conduct research and development in gene editing therapies for ocular diseases, valued up to US$1 billion
• Mapi Pharma’s Partnership with Mylan to develop and commercialize a product to treat multiple sclerosis
• Codexis’ Collaboration with Nestlé Health Science on protein engineering, valued up to US$357 million
• Revolution Medicines’ Partnership with Sanofi to develop and commercialize targeted therapies for cancer patients, valued up to US$500 million
• Puma Biotechnology’s out-license to Canbridge Life Sciences for rights to Puma’s proprietary cancer treatment Nerlynx in greater China, valued up to US$70 million
• Pear Therapeutics’ Collaboration with Sandoz (a division of Novartis) to commercialize two of its lead products, reSET® and reSET-O™, valued up to US$100 million
• Intuity Medical’s software development and license agreement with Motivation Medicine